推荐产品
形狀
solid
顏色
off-white
mp
267 °C
儲存溫度
2-8°C
SMILES 字串
OS(O)(=O)=O.NC(=N)N1CC(O)c2ccccc2C1.NC(=N)N3CC(O)c4ccccc4C3
InChI
1S/2C10H13N3O.H2O4S/c2*11-10(12)13-5-7-3-1-2-4-8(7)9(14)6-13;1-5(2,3)4/h2*1-4,9,14H,5-6H2,(H3,11,12);(H2,1,2,3,4)
InChI 密鑰
AETJLQVZNVTWPH-UHFFFAOYSA-N
應用
(±)-4-Hydroxydebrisoquin sulfate can be used for the metabolic studies of debrisoquin.
生化／生理作用
CYP2D6 metabolite of debrisoquin.
包裝
Bottomless glass bottle. Contents are inside inserted fused cone.
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
R Ismail et al.
Journal of clinical pharmacy and therapeutics, 25(5), 379-383 (2000-12-21)
Although they originated from China, Malays have undergone a lot of intermarriages. A study suggested that CYP2D6 poor metabolism (PM) phenotype was more common in Malays compared to Chinese. CYP2D6 is highly polymorphic and is involved in the metabolism of
R F Frye et al.
Journal of chromatography. B, Biomedical applications, 677(1), 178-182 (1996-02-23)
A sensitive and specific reversed-phase high-performance liquid chromatographic assay was developed for the determination of debrisoquine and 4-hydroxydebrisoquine in urine. The urine samples were directly injected following an ether clean-up step which eliminated interference. Separation of the analytes was achieved
L Bertilsson et al.
Pharmacogenetics, 3(2), 94-100 (1993-04-01)
Pronounced differences in the CYP2D6 gene between Chinese and Caucasians have previously been described. There was a low frequency of detrimental mutations in the Chinese CYP2D6 gene causing the poor metabolizer (PM) phenotype. In contrast to Caucasians where the Xba
M J Steiger et al.
Acta neurologica Scandinavica, 86(2), 159-164 (1992-08-01)
Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. There was no significant difference between the proportion of poor metabolisers of DBQ among YOPD patients
Miki Katoh et al.
Journal of pharmaceutical sciences, 96(2), 428-437 (2006-10-20)
We previously clarified that major human drug metabolizing enzymes were expressed in a chimeric urokinase-type plasminogen activator (uPA)+/+/severe combined immunodeficient (SCID) mouse line established recently, in which the liver could be replaced by more than 80% with human hepatocytes. In
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门